

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

THIS PAGE BLANK (USPTO)

Helsinki 7.8.2000

ETUOIKEUSTODISTUS
PRIORITY DOCUMENT



Hakija
Applicant

Galilaeus Oy
Piispanristi

EJU



Patenttihakemus nro
Patent application no

19992085

Tekemispäivä
Filing date

29.09.1999

Kansainvälinen luokka
International class

C12N

Keksinnön nimitys
Title of invention

"The gene cluster involved in aclacinomycin biosynthesis, and its use
for genetic engineering"
(Aklasinomysiinin biosynteesiin liittyvä geeniryhmittymä ja sen käyttö-
geenitekniikassa)

Täten todistetaan, että oheiset asiakirjat ovat tarkkoja jäljennöksiä
patentti- ja rekisterihallitukselle alkuaan annetuista selityksestä,
patenttivaatimuksista, tiivistelmästä ja piirustuksista.

This is to certify that the annexed documents are true copies of the
description, claims, abstract and drawings originally filed with the
Finnish Patent Office.

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Eija Solja
Eija Solja
Apulaistarkastaja

Maksu 300,- mk
Fee 300,- FIM

The gene cluster involved in aclacinomycin biosynthesis, and its use for genetic engineering

Field of the invention

5

This invention relates to the gene cluster for aclacinomycin biosynthesis derived from *Streptomyces galilaeus*, and the use of the genes included therein to obtain hybrid antibiotics, or to increase yields of aclacinomycins or related antibiotics.

10 Background of the invention

Anthracyclines are widely used anticancer agents. Seven different anthracyclines are in worldwide clinical use: daunorubicin, doxorubicin, idarubicin, epirubicin, pirarubicin, zorubicin and aclarubicin. A representative compound is doxorubicin, being the most efficient and acting on a wide array of malignancies. A variety of toxic effects, like cumulative cardiotoxicity found with doxorubicin has sometimes led to discontinuation of the treatment. Furthermore, there are some type of malignancies which do not respond to available anthracyclines. The mechanism of action of anthracyclines, reflecting to their clinical efficiencies, is not clear, although most researchers consider inhibition of topoisomerase II as a desired effect. Generation of free radicals derived from quinonic structures is suggested to be related to side effects such as cardiotoxicity. Anthracyclines have recently been reviewed by Professor Strohl and his group (1997).

Aclacinomycin A (aclarubicin) first described by Oki *et al.* (1975) is an anthracycline antibiotic produced by *Streptomyces galilaeus* ATCC 31133 and *S. galilaeus* ATCC 31615. It is active against tumor cells and exhibits alleviated toxic properties as compared with doxorubicin. However, its activity does not reach solid tumors, limiting its use in leukemia treatment. Aclarubicin differs from the other counterparts in its structure. A trisaccharide moiety, rhodosamine-2-deoxyfucose-cinerulose A is attached at C-7 by a glycosidic bond, whereas at the corresponding position of daunomycins only one sugar residue, daunosamine, is attached.

Despite the long history of anthracyclines, three decades or so, the studies on their biosynthesis are still going on, and there is further interest to obtain novel molecules for

the development of cancer chemotherapeutics. A method currently used for finding novel molecules for drug screening is genetic engineering. Cloning the genes for anthracycline biosynthesis facilitates the production of hybrid anthracyclines, as well as their use in combinatorial biosynthesis to generate novel molecules. As regards the
5 chemical nature of anthracyclines currently in clinical use, aclarubicin has unique features which make its biosynthetic genes interesting in creating novel products.

Regarding the genes for deoxyhexose pathway, Madduri *et al.* (1998) have reported that a gene derived from avermectin biosynthesis cluster caused the production of hybrid
10 anthracyclines altering a sugar moiety when transferred into a *S. peucetius* strain. The product obtained was epirubicin, a commercially important anthracycline. In this case a hydroxy group in the daunosamine moiety was in the opposite stereochemistry due to the action of an avermectin biosynthesis gene.

15 *S. galilaeus* has been used as the host to prepare hybrid anthracyclines using the genes derived from rhodomycin pathway from *S. purpurascens* (Niemi *et al.*, 1994) and from nogalamycin biosynthesis cluster from *S. nogalater* (Ylihonko *et al.*, 1996a). The genes for nogalamycin pathway were used to generate the hybrid anthracycline production in *S. steffisburgensis* producing typically steffimycin (Kunnari *et al.*, 1997). Previously,
20 biosynthesis genes for actinorhodin have been expressed in *S. galilaeus*, resulting in the formation of aloesaponarin (Strohl *et al.*, 1991). These hybrid compounds were modified in the aglycone moiety. Recently, the biosynthesis genes involved in deoxyhexose pathway of nogalamycin were used to generate hybrid compounds using the *S. galilaeus* mutants as hosts (FI pat. appln No. 982295).

25 As shown above, *S. galilaeus* has been used as a cloning host to generate novel molecules, whereas its use to donate the genes has not been described. The identified genes involved in aclacinomycin biosynthesis include polyketide reductase gene (Tsukamoto *et al.*, 1994), aklanonic acid methyl ester cyclase (GeneBank, ACCESSION
30 AF043550) and genes for polyketide synthase (Hutchinson and Fujii, 1995; the sequence not available).

Summary of the invention

The present invention concerns a gene cluster, most of the genes of which are derived from deoxyhexose pathway for rhodosamine, 2-deoxyfucose and/or rhodinos. The gene cluster was cloned from *S. galilaeus* ATCC 31615 and it is involved in biosynthesis of aclacinomycins.

Detailed description of the invention

10 The experimental procedures of the present invention include biochemical and chemical methods conventional in the art. Detailed description of the techniques not explained here are given in the manuals by Hopwood *et al.* 'Genetic manipulation of Streptomyces: a laboratory manual'. The John Innes Foundation, Norwich (1985) and by Sambrook *et al.* (1989) 'Molecular cloning: a laboratory manual'.

15

The publications, patents and patent applications cited herein are given in the reference list in their entirety.

The present invention concerns particularly the discovery of the gene cluster for aclacinomycin biosynthesis. The cluster, when introduced into *S. peucetius* strains caused the production of hybrid antibiotics modified in their sugar moiety.

Several strategies may be adopted to clone genes for an antibiotic. Using *E. coli* as a host for a gene library, hybridization is the most advantageous screening strategy. The probe for hybridization may be any known fragment that shows sufficient homology to the biosynthetic cluster for aclarubicin sugars, to be able to hybridize with said cluster. A DNA fragment which is identical to the desired region is preferred. Such a fragment, called Sg-dht, was obtained by PCR amplification of *S. galilaeus* chromosomal DNA, using degenerated oligonucleotides annealing to the conserved region of 4,6-dehydratase gene. 4,6-dehydratase is the first enzyme participating to a reaction series that converts a glucose molecule bound to a nucleotide into 6-deoxy sugars generally found in antibiotics. Using this probe it was possible to clone the cluster of deoxyhexose pathway

from a restricted gene library. To simplify the cloning strategy the library was prepared in a pUC-based plasmid (e.g. pBluescript or pWHM1109) replicating in *E. coli*.

The strategy to clone the genes involved in aclacinomycin biosynthesis according to the invention was in brief: Total DNA was isolated from *S. galilaeus* (ATCC 31615) and digested with several restriction enzymes that yield fragments of 10 kb in average. Restriction fragments were analyzed by Southern hybridization using a homologous DNA fragment, Sg-dht, as a probe. *Bgl*II gave a hybridized fragment of 8.5 kb, and a double digestion with *Xho*I and *Not*I gave a hybridized fragment of 7 kb. DNA digestion using (i) *Bgl*II and (ii) *Xho*I-*Not*I was carried out and the fragments were ligated to the *E. coli*-*Streptomyces* shuttle vector, pWHM1109, digested with *Bam*HI and to the pBluescript digested with *Xho*I-*Not*I, respectively. The ligation mixtures were introduced into *E. coli* XL1BlueMRF' that exhibits alleviated restriction-modification systems. Colonies were plated on the agar plates in the dilution to give 200 to 600 cfu (colony forming units) per plate. Well grown colonies were transferred in nylon membranes for hybridization, which was carried out using the Sg-dht probe. Six out of the 786 *Bgl*II-digested clones gave hybridization signal and 7 out of 1523 of those clones carrying *Xho*I-*Not*I fragments. Hybridization and washes were carried out in the stringent conditions of 65°C in a low salt concentration. Several techniques for the labeling of the probe and for hybridization are possible, but the procedure according to Boehringer Mannheim's "The DIG System User's Guide for Filter Hybridization" is preferred. The colonies giving hybridization signals were cultivated for plasmid isolation. The plasmids were analyzed by Southern hybridization to confirm the reliability of the colony hybridization. Plasmids containing the desired DNA fragments (Sg4 and Sg5) were designated as pSgc4 (*Bgl*II-fragment) and pSgc5 (*Xho*I-*Not*I fragment)(see Fig. 2).

The fragments, Sg4 and Sg5, were subcloned for sequencing in *E. coli* vectors pUC19 and pBluescript. In total 30 subclones were used to obtain the nucleotide sequence of Sg4 and Sg5. The sequenced cluster revealed thirteen genes involved in biosynthesis of aclacinomycins. Comparison with the sequences found in the sequence library suggested the functions as *sga*2 for an activator, *sga*3 for a dehydratase, *sga*4 for oxidoreductase, *sga*5 for dTDP-glucose 4,6-dehydratase, *sga*6 for glycosyl transferase (GTF), *sga*7 for

a putative isomerase, *sga8* for aklaviketone reductase, *sga9* for a putative polyketide assembler, *sga10* for a putative cyclase, *sga11* for aminomethylase, *sga12* for glucose-1-phosphate thymidyl transferase, *sga13* for aminotransferase. The function of *sga1* is not suggested based on similarity searches. Based on the deduced functions, nine genes are involved in glycosylation pathway. The genes involved in the formation of aglycone are *sga8*, *sga9*, and *sga10*. The activator, Sga2, may control both the glycosylation system and the formation of aklavinone via polyketide pathway.

Sg4 derived from pSgc4 was cloned in the *Streptomyces* expression vector pIJE486 (Ylihonko *et al.*, 1996b) in *S. lividans* TK24 to give pSgs4. This vector is a high copy number plasmid that replicates in several *Streptomyces* spp. (Ward *et al.*, 1986) and it contains a constitutively expressed promoter, *ermE* (Bibb *et al.*, 1985) upstream from the multiple cloning site. The plasmid pSgs4 isolated from TK24 was introduced into the *S. galilaeus* strains that are blocked in deoxyhexose pathway of aclacinomycin biosynthesis and into the *S. peucetius* mutants producing ϵ -rhodomycinone based on a lesion in glycosylation genes. The ability of aclacinomycin production was restored by three *S. galilaeus* mutants, H063, H054 and H065. The mutant strain H063 accumulates aklavinone and it was completely complemented by the plasmid pSgs4. Instead, H054 and H065 producing aklavinone glycosides sharing neutral sugars, but not rhodosamine, were only partially complemented by pSgs4. Surprisingly, H063 carrying pSgs4 (H063/pSgs4) was able to produce aclacinomycins two-fold to that of the wild type *S. galilaeus*. *S. peucetius* M18 and M90 which produce ϵ -rhodomycinone were selected to hosts for pSgs4. L-rhamnosyl- ϵ -rhodomycinone (El Khaled *et al.*, 1977) was obtained when pSgs4 was expressed in the mutants M18 and M90 and, in addition, M18/pSgs4 produced L-daunosaminy- ϵ -rhodomycinone (Essery and Doyle, 1980). The structures were not new ones but this demonstrates the ability of the gene cluster according to the present invention to generate hybrid products in a heterologous host. To produce hybrid compounds we prefer to use E1 medium supplemented with a suitable antibiotic, in this case, thiostrepton, to maintain the selection pressure for the plasmid containing strains. The products were extracted by organic solvents and purified by chromatography to obtain the compounds in high purity for structural elucidation.

Examples to further illustrate the invention are given hereafter.

Brief description of the drawings

FIG. 1 shows the structures of aclacinomycin, daunomycin and ϵ -rhodomycinone.

5 FIG. 2 is a diagram of the gene cluster for aclacinomycin biosynthesis.

FIG. 3 describes the proposed biosynthesis pathway for sugars found in aclacinomycins.

10 FIG. 4 shows the structures of the hybrid compounds produced by M18/pSgs4 (1 and 2) and M90/pSgs4 (2).

EXPERIMENTAL

15 Materials used

Restriction enzymes used were purchased from Promega (Madison, Wisconsin, USA), Fermentas (Lithuania) or Boehringer Mannheim (Germany), alkaline phosphatase from Boehringer Mannheim, and used according to manufacturers' instructions. Proteinase K
20 was purchased from Promega and lysozyme from Sigma. HybondTM-N nylon membranes used in hybridization were purchased from Amersham (Buckinghamshire, England), DIG DNA Labelling Kit and DIG Luminescent Detection Kit from Boehringer Mannheim. Qiaquick Gel Extraction Kit from Qiagen (Hilden, Germany) was used for isolating DNA from agarose.

25

Bacterial strains and their use

Escherichia coli XL1BlueMRF' (Stratagene, La Jolla, California) was used for cloning.

30 *Streptomyces lividans* TK24 was the first cloning host for gene expression. The strain was provided by prof. Sir David Hopwood, John Innes Centre, UK.

The wild type, *Streptomyces galilaeus* ATCC 31615, produces aclacinomycins. It was used here to donate the genes of the invention.

5 *Streptomyces galilaeus* H039 (Ylihonko *et al.*, 1994) produces Akv-(Rho)₀₋₃. It was used as an expression host for pSgs4 being more easily transformed than the other mutants or the wild type.

10 *Streptomyces galilaeus* H054 (Ylihonko *et al.*, 1994) produces Akv-Rho-dF-(CinA)₀₋₁, Akv-dF-dF-(CinA)₀₋₁ and Akv-dF-Rho-Rho. It was used as an expression host for pSgs4.

Streptomyces galilaeus H063 produces aklavinone. It is a mutant strain derived from the wild type *S. galilaeus*. H063 was used as an expression host for pSgs4.

15 *Streptomyces galilaeus* H065 produces aklavinone with neutral glycosides. It is a mutant strain derived from the wild type *S. galilaeus*. H065 was used as an expression host for pSgs4.

20 *Streptomyces peucetius* M18 and M90 producing ϵ -rhodomycinone are the mutants derived from *S. peucetius* var. *caesi*us (ATCC 27952). They were used as expression hosts for pSgs4.

Plasmids

25 *E. coli* cloning vectors pBluescript SK (Stratagene) and pUC19 (Pharmacia, Sweden) were used for making the subclones for sequencing and pBluescript was used also as a vector of a gene library.

30 pWHM1109 (provided by prof CR Hutchinson, Wisconsin, USA) is a shuttle vector replicating in *E. coli* and in streptomycetes. It was used as a vector of a gene library.

pIJ486 is a high copy plasmid vector provided by prof. Sir David Hopwood, John Innes Centre, UK (Ward *et al.*, 1986).

pIJE486 (Ylihonko *et al.*, 1996b) is an expression vector containing *ermE* (Bibb *et al.*, 1985) to promote expression of the cloned genes.

Nutrient media and solutions

5

For cultivation of *S. galilaeus* for total DNA isolation TSB medium was used. Lysozyme solution (0.3 M sucrose, 25 mM Tris, pH 8 and 25mM EDTA, pH 8) was used to isolate total DNA. TE buffer (10 mM Tris, pH 8.0 and 1mM EDTA) was used to dissolve DNA.

10

TRYPTONE-SOYA BROTH (TSB)

Per litre: Oxoid Tryptone Soya Broth powder 30 g.

ISP4

15 Bacto ISP-medium 4, Difco; 37 g/l.

E1 Per litre in tap water:

	glucose	20 g
	soluble starch	20 g
20	Farmamedia	5 g
	Yeast extract	2.5 g
	K ₂ HPO ₄ ·3H ₂ O	1.3 g
	MgSO ₄ ·7H ₂ O	1 g
	NaCl	3 g
25	CaCO ₃	3 g

pH adjusted to 7.4 before autoclaving

General methods:

30 NMR data was collected with a JEOL JNM-GX 400 spectrometer. ¹H and ¹³C NMR samples were internally referenced to TMS.

The anthracycline metabolites were determined by (i) HPLC (LaChrom, Merck Hitachi, pump L-7100, detector L-7400 and integrator D-7500) using a LiChroCART RP-18
35 column. Acetonitrile:potassium hydrogen phosphate buffer (60 mM, pH 3.0 adjusted

with citric acid) was used as a mobile phase. Gradient system starting from 65 % to 30 % of potassium dihydrogen phosphate buffer was used to separate the compounds. The flow rate was 1 ml/min and the detection was carried out at 480 nm, and (ii) by TLC using precoated Kieselgel 60 F₂₅₄ glass plates (Merck, Darmstadt, Germany) with an elution solution of toluene:ethyl acetate:methanol:formic acid (50:50:15:3).

ISP4 plates supplemented with thiostrepton (50 µg/ml) were used to maintain the plasmid carrying cultures.

10 Example 1. Cloning the gene cluster for aclacinomycin biosynthesis

1.1 Selection of clones by hybridization

For isolation of total DNA, *Streptomyces galilaeus* was grown for four days in 50 ml of TSB medium supplemented with 0.5% glycine. The cells were harvested by centrifuging for 15 min (3900 x g) in 12 ml Falcon tubes, and stored at -20°C. Cells from a 50 ml culture were used to isolate DNA. 5 ml of lysozyme solution containing 5 mg/ml of lysozyme was added on the cells of each Falcon tube, and incubated for 20 min at 37°C. 500 µl of 10% SDS containing 0.7 mg of proteinase K was added on the cells, and incubated for 80 min at 62°C, another 500 µl of 10% SDS containing 0.7 mg of proteinase K was added, and incubation was continued for 60 min. The sample was chilled on ice and 600 µl of 3M NaAc, pH 5.8 was added, and the mixture was extracted with equilibrated phenol (Sigma). The phases were separated by centrifuging (1400 x g) for 10 min. The DNA was precipitated from the water phase with an equal volume of isopropanol and collected by spooling with a glass rod and washed by dipping into 70% ethanol, air dried and dissolved in 500 µl of TE-buffer.

Southern hybridization to determine suitable restriction enzymes for preparing the restricted plasmid libraries was carried out using *Bgl*II, *Xho*I, *Not*I and their combinations. A fragment of about 9 kb hybridizing with the Sg-dht probe was preferred. For hybridization 600 ng of digested *S. galilaeus* DNA was loaded onto the agarose gel and after electrophoresis, the DNA was transferred from the gel to a nylon membrane by vacuum blotting. Hybridization was carried out according to Boehringer Mannheim's

manual 'The DIG System User's Guide for Filter Hybridization'. The probe for hybridization, Sg-dht, which was used for colony hybridization as well, was obtained by amplifying a gene fragment from the *S. galilaeus* DNA which is internal to the 4,6-dehydratase gene and corresponds to the fragment of 6345 to 6861 shown in SEQ ID NO:14. PCR was used for amplification, and the sequences for the degenerated oligonucleotide primers were 5'-CSGGSGSSGCSGGSTTCATSGG-3' (forward, SEQ. ID. NO:15) and 5'-GGGWRCTGGYRSGGSCCGTAGTTG-3' (reverse, SEQ. ID. NO:16). Suitable fragments were a 9 kb *Bgl*III fragment and a 7 kb *Xho*I-*Not*I fragment.

10 Ten micrograms of the chromosomal DNA was digested with *Bgl*III. The DNA fragments were separated by agarose gel electrophoresis and the band of 8 to 9 kb were cut from the 0.6% low gelling temperature SeaPlaque® agarose. The DNA band was isolated from the gel using Qiagen Gel Extraction Kit. The isolated fragment was ligated to pWHM1109 plasmid vector digested with *Bam*HI and defosforylated, in the ratio of 3 moles of the insert DNA to 1 mole of the vector DNA. The ligated DNA was introduced into *E. coli* XL1BlueMRF' by electroporation. Using the whole ligation mixture 786 colonies were obtained. The colonies were grown on agar plates for at least 12 h and transferred to nylon membranes. Hybridization of colony membranes was carried out as Southern using Sg-dht as a probe. Six clones gave signal in hybridization and the corresponding colonies were plated on agar and inoculated in 3 ml of LB medium for isolation of the plasmid DNA. Southern hybridization was used to study whether the plasmids derived from the clones carried the desired insert. Four of these plasmids contained the 4,6-dehydratase gene fragment and gave the identical restriction map thus carrying the same fragment representing both orientations. The fragment was designated as Sg4 and the plasmid containing the fragment as pSgc4.

In the same manner the plasmid library representing a 7 kb *Xho*I-*Not*I DNA fragment derived from *S. galilaeus* was constructed. pBluescript was digested with *Xho*I-*Not*I and the library containing the gene fragments of around 7 kb was constructed. In total 1523 colonies were hybridized and seven turned to be the desired clone. As described above, the clones were studied for the *Xho*I-*Not*I fragment. The insert fragment was designated as Sg5 and the plasmid as pSgc5. The strain *E. coli* XL1Blue MRF'/pSgc5 obtained was deposited according to the rules of the Budapest Treaty at Deutsche Sammlung von

Mikroorganismen und Zellkulturen GmbH (DSMZ) on August 12, 1999 with the accession number DSM 12999. The fragments Sg4 and Sg5 overlap within 836 bp corresponding bases from 6181 to 7016 in SEQ ID NO:14.

5 1.2. Subcloning the fragments for sequencing

To determine the nucleotide sequence of the whole cluster of the Sg4 and Sg5 suitable subclones were constructed. The convenient restriction sites were used for subcloning the 14806 bp region in the plasmids pUC19 and pBluescript. Nineteen subclones were
10 needed to sequence Sg4, and 11 subclones for Sg5.

E. coli XL1BlueMRF' cells containing the subcloned plasmids were cultivated overnight at 37°C in 5 ml of LB-medium supplemented with 50 µg/ml of ampicillin. To isolate plasmids for sequencing reactions Wizard Plus Minipreps DNA Purification
15 System kit of Promega or Biometra Silica Spin Disc Plasmid DNA Miniprep kit of Biomedizinische Analytik GmbH were used according to the manufacturers' instructions.

DNA sequencing was performed using the automatic ABI DNA sequencer (Perkin-Elmer) according to the manufacturer's instructions.

20

1.3 Sequence analysis and the deduced functions of the genes

Sequence analyses were made using the GCG sequence analysis software package (Version 8; Genetics Computer Group, Madison, Wis., USA). The translation table was
25 modified to accept also GTG as a start codon. Codon usage was analyzed using published data (Wright and Bibb 1992).

According to the CODONPREFERENCE program the sequenced DNA fragment revealed 11 complete open reading frames (ORFs), and two 5' ends of the other ORFs
30 (*sga1* and *sga13*). The functions of the genes were concluded by comparing the amino acid sequences translated from their base sequences to the known sequences in the data banks. The results are shown in Table 1 referring to the sequence data given in the application.

The suggested functions for the genes match well with a proposed biosynthetic pathway of sugars of aclacinomycins (Fig. 3). The last residue in a trisaccharide moiety of aclacinomycins is rhodnose that is enzymatically converted to cinerulose. Aclacinomycin N, a precursor of aclarubicin, contains rhodnose as the third sugar residue.

5

Table 1.

Gene	Position	Amino acids	Deduced function	Remarks
<i>sga1</i>	-1986 compl	>662	unknown	not complete Seq.ID.NO:1
<i>sga2</i>	2523-3341	272	activator	Seq.ID.NO:2
<i>sga3</i>	3355-4659 compl	434	dehydratase	Seq.ID.NO:3
<i>sga4</i>	4821-5810	329	oxidoreductase	Seq.ID.NO:4
<i>sga5</i>	5920-6891 compl	323	dTDP-glucose 4,6-de- hydratase	Seq.ID.NO:5
<i>sga6</i>	6879-8210 compl	443	glycosyl transferase (GTF)	Seq.ID.NO:6
<i>sga7</i>	8287-9618 compl	443	putative isomerase	Seq.ID.NO:7
<i>sga8</i>	9642-10445 compl	267	aklaviketone reductase (KR11)	Seq.ID.NO:8
<i>sga9</i>	10471-10905 compl	144	putative polyketide assembler	Seq.ID.NO:9
<i>sga10</i>	11115-11894	259	putative cyclase	Seq.ID.NO:10
<i>sga11</i>	11956-12672	238	aminomethylase	Seq.ID.NO:11
<i>sga12</i>	12685-13560 compl	291	glucose-1-phosphate thymidyltransferase	Seq.ID.NO:12
<i>sga13</i>	13783-14805	341	aminotransferase	Seq.ID.NO:13 not complete

1.4 Expression cloning in *Streptomyces* strains

25

The 8 kb *Bam*HI-*Hind*III fragment from pSgc4 was ligated in pIJE486 to give pSgs4. Plasmid pSgs4 was introduced into *S. lividans* TK24 by protoplast transformation. The strain *S. lividans* TK24/pSgs4 obtained was deposited according to the rules of the

Budapest Treaty at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) on August 12, 1999 with the accession number DSM 12998. The plasmid pSgs4 was isolated from the strain, and further transferred into *S. galilaeus* mutant H039. The plasmid prepare isolated from H039 was subsequently introduced into
5 H063, H054, and H065 mutants deficient of glycosylation system of aclacinomycins. The usage of H039 as a primary *S. galilaeus* host was due to the better efficiency for the intake of foreign DNA.

S. galilaeus mutants were studied for complementation by cultivating the clones
10 containing pSgs4 in E1 medium supplemented with thiostrepton (10 µg/ml). The products from a 500 µl sample of the culture broth were extracted with toluene:methanol (1:1) at pH 7. The metabolites from both the transformed clones and the mutants were analyzed by TLC and HPLC to find the differences caused by pSgs4. H063 producing endogenously aklavinone was restored to aclacinomycin producer with
15 pSgs4. No aklavinone was found in the culture broth of H063/pSgs4. However, complementation was not completed when pSgs4 was expressed in H054 and H065. Both of the mutants produce aklavinone with neutral glycosides. Incomplete complementation was presumably due to the loss of the plasmids of some bacterial cells during cultivation, or a low expression of the genes needed as an activator is not present in
20 pSgs4.

In the same manner, pSgs4 isolated from TK24 was introduced into the *S. peucetius* mutants M18 and M90. The characteristic product for these mutants is ε-rhodomycinone. The strains M18/pSgs4 and M90/pSgs4 containing the plasmid were cultivated in E1
25 medium supplemented with thiostrepton (10 µg/ml), and the metabolites therein were analyzed by TLC and HPLC. Both of the clones revealed an altered production profile as compared with the products obtained from the mutants. M90/pSgs4 accumulated a glycosylated product, yielding ε-rhodomycinone as the aglycone. The compound was identified as L-rhamnosyl-ε-rhodomycinone which has been previously synthesized
30 (CAS=63252-11-9) by El Khamed *et al.* (1977).

M18/pSgs4 produced two compounds differing from the parental strain. According to the HPLC and TLC data one compound was the same as was produced by M90/pSgs4,

L-rhamnosyl- ϵ -rhodomycinone, and the other one was L-daunosaminy- ϵ -rhodomycinone, which was previously characterized by Essery and Doyle (1980).

Table 2: TLC and HPLC data of the hybrid products

Product	Rf-value	Retention time
ϵ -rhodomycinone	0.67	6.70
L-rhamnosyl- ϵ -rhodomycinone	0.38	5.00
L-daunosaminy- ϵ -rhodomycinone	0.04	4.06

1.5 Applicability of pSgs4 for strain improvement

Since H063 was completely complemented by pSgs4, the production level of aminoglycosides was studied. For this purpose, H063/pSgs4, H063 and the wild type *S. galilaeus* were cultivated in E1 medium in the Erlenmeyer bottles for four days. Two samples of 2 ml from each culture were extracted first with toluene:methanol (1:1) in acidic conditions to remove the neutral glycosides and the aglycones. The extraction procedure was repeated until neutral glycosides and the aglycones had disappeared from the water phase. The amount of anthracycline metabolites in toluene phase was determined and is shown in Table 3. Aclacinomycins containing rhodosamine were extracted from the water phase by chloroform. Both toluene and chloroform extracts were analyzed by TLC and toluene phases contained mostly aklavinone and the degradative products. Chloroform phases contained mainly aminoglycosides, although minor amounts of the aglycones were also detected. Extracts were evaporated to dryness and subsequently dissolved into 1 ml of methanol. The amounts of anthracycline metabolites were detected by spectrophotometer at 430 nm. The amounts related to absorbance were calculated using an extinction coefficient of 13000. The results given as mg/l of cultivation broth are shown in Table 3. The production of aclacinomycins by H063/pSgs4 was at least twofold better than obtained by the wild type.

Table 3.

Sample	Chloroform phase aminoglycoside fraction		Toluene phase aglycone fraction	
	Absorbance	Concentration (mg/l)	Absorbance	Concentration (mg/l)
H063	0.401	12.6	2.956	92.3
H063/pSgs4	2.751	85.9	2.974	92.9
<i>S. galilaeus</i>	1.338	41.8	0.690	21.5

- 10 The ability to increase the yield of aclacinomycins by pSgs4 in the mutant H063 suggests that the genes according to the present invention are useful in strain improvement.

Example 2. Compounds generated by pSgs4

15

The seed culture, 180 ml of E1 culture of the plasmid containing strains, M18/pSgs4 or M90/pSgs4, was obtained by cultivating each of the strains in three 250 ml Erlenmeyer flasks containing 50 ml of E1-medium supplemented with thiostrepton (5 µg/ml) for four days at 30°C, 330 rpm. The combined culture broths (180 ml) were used to inoculate 13 l of E1-medium in a fermentor (Biostat E). Fermentation was carried out for five days at 28°C (330 rpm, aeration: 450 l/min).

The cells were harvested by centrifuging. 2.6 l of methanol was used to brake the bacterial cells. The anthracycline metabolites were extracted from methanol solution at pH 8 using 2 l of ethyl acetate and the extract was evaporated to dryness. The viscous residue was loaded onto a silica column of 4 × 10 cm and toluene:ethyl acetate:formic acid (50:50:3) with increasing amount of methanol was used as an eluent. Pure fractions were pooled and extracted with 1M phosphate buffer (pH 8.0) and water. Organic phase

was dried with anhydrous Na_2SO_4 and then treated with hexane to effect precipitation. Pure compounds appeared as red powders dried under vacuum.

Complete structural determination of the compounds were accomplished by NMR.

- 5 Proton and carbon assignments were based on a conventional NOE difference, pHSQC and HMBC measurements. Connectivities in particular relied heavily on HMBC experiment.

- 10 As deduced from the data given in Table 4, the structures revealed were L-rhamnosyl- ϵ -rhodomycinone (1) and L-daunosaminy- ϵ -rhodomycinone (2) shown in Figure 4.

- 15 Although these structures were not novel, the generation of the hybrid products by the genes involved in glycosylation portion of aclacinomycin biosynthesis well demonstrates that the genes of pSgs4 are functional and ready to use in drug discovery for finding novel molecules.

Deposited microorganisms

- 20 The following microorganisms were deposited according to the Budapest Treaty at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig, Germany.

	Microorganism	Accession number	Date of deposit
25	<i>S. lividans</i> TK24/pSgs4	DSM 12998	12 August 1999
	<i>E. coli</i> XL1BlueMRF'/pSgc5	DSM 12999	12 August 1999

Table 4. ^1H and ^{13}C chemical shifts of 1 (DMSO_{d6}) and 2 (trace of TFA in DMSO_{d6}) in 400 and 100 MHz respectively.

Site	1		2	
	^1H	^{13}C	^1H	^{13}C
1	7.74, 1H, dd, 7.5, 0.9	118.9(d)	7.74, 1H, dd, 7.5, 1.0	119.7(d)
2	7.64, 1H, dd, 8.4, 7.5	136.5(d)	7.68, 1H, dd, 8.1, 7.5	137.4(d)
3	7.22, 1H, dd, 8.4, 0.9	124.1(d)	7.24, 1H, dd, 8.1, 1.0	125.0(d)
4	–	161.8(s)	–	162.6(s)
4-OH	12.00, 1H, s	–	exchange broadened	–
4a	–	115.2(s)	–	115.9(s)
5	–	189.9(s)	–	190.6(s)
5a	–	110.4(s)	–	111.4(s)
6	–	156.2(s)	–	157.1(s)
6-OH	13.41, 1H, s	–	exchange broadened	–
6a	–	135.1(s)	–	135.7(s)
7	5.14, 1H, d, 4.5	70.9(d)	5.15, 1H, d, 3.6	71.3(d)
8A	2.31, 1H, d, 15.1	28.9(t)	2.33, 1H, d, 14.6	34.0(t)
8B	2.14, 1H, dd, 15.1, 4.5	–	2.21, 1H, dd, 14.6, 3.8	–
9	–	70.0(s)	–	70.9(s)
10	4.16, 1H, s	51.2(d)	4.23, 1H, s	51.8(d)
10a	–	134.8(s)	–	136.1(s)
11	–	156.0(s)	–	156.8(s)
11-OH	12.77, 1H, s	–	exchange broadened	–
11a	–	110.8(s)	–	111.1(s)
12	–	185.4(s)	–	186.0(s)
12a	–	132.6(s)	–	133.3(s)
13A	1.73, 1H, dq, 13.9, 7.4	31.7(t)	1.83, 1H, dq, 14.1, 7.3	32.0(t)
13B	1.38, 1H, dq, 13.9, 7.4	–	1.47, 1H, dq, 14.1, 7.3	–
14	1.05, 3H, t, 7.4	6.09(q)	1.13, 3H, t, 7.3	6.90(q)
15	–	170.4(s)	–	171.1(s)
16	3.63, 3H, s	51.7(q)	3.70, 3H, s	52.3(q)
1'	5.28, 1H, brs	103.7(d)	5.52, 1H, d, 3.1	100.7(d)
2'	3.83, 1H, d, 5.2	70.9(d)	2.18, 2H, m	27.1(t)
3'	3.44, 1H, dd, 9.0, 5.2	70.8(d)	3.40, 1H, dd, 11.8, 5.1	55.5(d)
4'	3.41, 1H, dd, 9.1, 9.0	72.0(d)	3.98, 1H, brs	67.0(d)
5'	3.77, 1H, dq, 9.1, 6.2	68.9(d)	4.21, 1H, q, 6.3	65.3(d)
6'	1.29, 3H, d, 6.2	16.9(q)	1.32, 3H, t, 6.3	16.7(q)

References

- Bibb, M. J., Janssen, G. R., and Ward, J. M. 1985. Cloning and analysis of the promoter region of the erythromycin resistance gene (*ermE*) of *Streptomyces erythraeus*. Gene 38: 215-226.
- El Khamed, H.S., Swartz, D.L., and Cermak, R.C. 1977. Synthesis of ϵ -rhodomycinone glycosides. J Med Chem 20: 957-960.
- Essery, J.M., and Doyle, T.W. 1980. The synthesis of daunosaminy- ϵ -rhodomycinone, daunosaminy-10- ϵ -rhodomycinone, daunosaminy- ϵ -pyrromycinone and 10-descarbomethoxy- ϵ -pyrromycin. Can J Chem 58: 1869-1874.
- Hutchinson, C.R., and Fujii, I. 1995. Polyketide synthase gene manipulation: A structure-function approach in engineering novel antibiotics. Annu Rev Microbiol 49: 201-238.
- Kunnari, T., Tuikkanen, J., Hautala, A., Hakala, J., Ylihonko, K., and Mäntsälä, P. 1997. Isolation and characterization of 8-demethoxy steffimycins and generation of 2,8-demethoxy steffimycins in *Streptomyces steffisburgensis* by the nogalamycin biosynthesis genes. J Antibiot 50: 496-501.
- Madduri, K., Kennedy, J., Rivola, G., Inventi-Solari, A., Filippini, S., Zanuso, G., Colombo, A.L., Gewain, K.M., Occi, J.L., MacNeil, D.J., and Hutchinson, C.R. 1998. Production of the antitumor drug epirubicin (4'-epidoxorubicin) and its precursor by a genetically engineered strain of *Streptomyces peucetius*. Nature Biotech 16: 69-74.
- Niemi, J., Ylihonko, K., Hakala, J., Kopio, A., Pärssinen, R., and Mäntsälä, P. 1994. Hybrid anthracycline antibiotics: production of new anthracyclines by cloned genes from *Streptomyces purpurascens* in *Streptomyces galilaeus*. Microbiol 140: 1351-1358.
- Oki, T., Matsuzawa, Y., Yoshimoto, A., Numata, K., Kitamura, I., Hori, S., Takamatsu, A., Umezawa, H., Ishizuka, M., Naganawa, H., Suda, H., Hamada, M., and Takeuchi, T. 1975. New antitumor antibiotics, Aclacinomycins A and B. J Antibiot 28: 830-834.
- Strohl, W. R., Dickens, M. L., Rajgarhia, V. B., Woo, A. J., and Priestley, N. D. 1997. Anthracyclines in Biotechnology of Antibiotics, ed. Strohl, W. R. Marcel Dekker Inc., New York. pp. 577-657.
- Strohl, W.R., Bartel, P.L. Li, Y., Connors, N.C., and Woodman, R.H. 1991. Expression of polyketide biosynthesis and regulatory genes in heterologous streptomycetes. J Ind Microbiol 7: 3: 163-174.
- Tsukamoto, N., Fujii, I., Ebizuka, Y., and Sankawa, U. 1994. Nucleotide sequence of the *aknA* region of the aklavinone biosynthetic gene cluster of *Streptomyces galilaeus*. J Bacteriol 176: 2473-2475.

- Ward, J. M., Janssen, G. R., Kieser, T., Bibb, M. J., Buttner, M. J., and Bibb, M. J. 1986. Construction and characterization of a series of multicopy promoter-probe plasmid vectors for *Streptomyces* using the aminoglycoside phosphotransferase from Tn5 as indicator. *Mol Gen Genet* **203**: 468-478.
- 5 Wright, F., and Bibb, M. J. 1992. Codon usage in the G+C-rich *Streptomyces* genome. *Gene* **113**: 55-65.
- 10 Ylihonko K., Hakala J., Kunnari T., and Mäntsälä P. 1996a. Production of hybrid anthracycline antibiotics by heterologous expression of *Streptomyces nogalater* nogalamycin biosynthesis genes. *Microbiol* **142**: 1965-1972.
- 15 Ylihonko, K., Tuikkanen, J., Jussila, S., Cong, L., and Mäntsälä, P. 1996b. A gene cluster involved in nogalamycin biosynthesis from *Streptomyces nogalater*: sequence analysis and complementation of early-block mutations in the anthracycline pathway. *Mol Gen Genet* **251**: 113-120.
- 20 Ylihonko, K., Hakala, J., Niemi, J., Lundell, J., and Mäntsälä, P. 1994. Isolation and characterization of aclacinomycin A-non-producing *Streptomyces galilaeus* (ATCC 31615) mutants. *Microbiol* **140**: 1359-1365.

SEQUENCE LISTING

<110> Galilaeus Oy

<120> The gene cluster involved in aclacinomycin biosynthesis, and its use for genetic engineering

<130> 31344

<140>

<141>

<160> 16

<170> PatentIn Ver. 2.2

<210> 1

<211> 662

<212> PRT

<213> *Streptomyces galilaeus*

<400> 1

```

Met Thr Glu Asp Arg Val Thr Thr Leu Gly Gly Glu Gln Ile Ala Leu
 1          5          10          15

Leu Ala Pro Leu Leu Asp Gly Ser Arg Asp Leu Pro Gly Ile Val Ala
          20          25          30

Asp Ala Ala Pro Arg Leu Pro Ala Gly Leu Ala Glu Arg Leu Val Thr
          35          40          45

Arg Leu Leu Asp Ala Gly Leu Leu Cys Ala Tyr Pro Gln Asp Gly Ala
 50          55          60

Asp Arg Pro Glu Arg Ala Tyr Arg Ser Leu Thr Gly Leu Gln Ala Arg
 65          70          75          80

Ser Ala Asp Ala Arg Asp Ala Val Leu Ala Ala Val Asp Leu Thr Gly
          85          90          95

Asp Ala Glu Ser Pro Leu Pro Glu Ala Val Ser Ala Ala Gly Leu Arg
          100          105          110

Ala Ala Ala Pro Gly Glu His Ala Ala Leu Thr Leu Val Leu Cys His
          115          120          125

Asp Tyr Leu Asp Pro Arg Leu Ser Ala Leu Asp Ala Glu His Arg Ala
          130          135          140

Thr Gly Arg Gly Trp Leu Pro Val Arg Ala Asn Gly Thr His Leu Trp
          145          150          155          160

Ile Gly Pro Phe Phe Ser Ala Gly Asp Gly Pro Cys Trp Ser Cys Leu
          165          170          175

Ala Asp Arg Leu Arg Leu Arg Arg Arg Gly Glu Ala Tyr Val Gln His
          180          185          190

Arg Leu Gly His Ser Gly Pro Ala Val His Arg Arg Ala Tyr Leu Pro
          195          200          205

Ala Gly Arg Ala Ala Ala Leu Gln Leu Ala Leu Leu Glu Ala Gly Lys
          210          215          220

Trp Leu Ser Gly His Arg Asp Thr Val Gln Asp Ser Leu Trp Arg Leu
          225          230          235          240

```

Asp Thr Arg Thr Leu Glu Ser Ser Arg His Pro Val Arg Arg Arg Pro
 245 250 255
 Gln Cys Ser Arg Cys Gly Asp Pro Leu Leu Val Arg Asp Arg Val Ser
 260 265 270
 Ala Pro Val Val Leu Ser Ser Arg Pro Val Arg Asp Glu Ser Gly Gly
 275 280 285
 Gly His Arg Thr Phe Gly Pro Gln Glu Met Leu Asp Arg Tyr Gly His
 290 295 300
 Leu Val Asp Pro Val Thr Gly Val Val Gly Glu Ile Arg Arg Asp Pro
 305 310 315 320
 Arg Gly Pro Glu Phe Leu Asn Cys Phe Thr Arg Ser Arg Cys Arg Leu
 325 330 335
 Gly Pro Arg Ala Ala Pro Pro Ala Leu His Ser Pro Leu Arg Ser Pro
 340 345 350
 Gly Ser Gly Lys Gly Val Thr Glu Leu His Ala Arg Val Ser Ala Leu
 355 360 365
 Ala Glu Ala Leu Glu Arg Cys Ser Gly Tyr Phe Gln Gly Asp Glu Pro
 370 375 380
 Arg Arg Arg Gly Ser Tyr Arg Glu Leu Ala Gly Leu Ala Val His Pro
 385 390 395 400
 Asp Ser Val Gln Leu Phe Asp Arg Arg Gln Phe Glu Asp Arg Arg Ala
 405 410 415
 Trp Asn Arg Ala His Gly Pro Phe His Gln Val Thr Glu Pro Phe Asp
 420 425 430
 Glu Asp Ala Pro Ile Asp Trp Thr Pro Val Trp Ser Leu Thr Glu Arg
 435 440 445
 Arg Gln Arg Leu Ala Pro Thr Ser Leu Leu Tyr Tyr Asn Ala Pro Asp
 450 455 460
 Ala Asp Thr Gly Phe Cys Arg Ala Thr Ser Asn Gly Ala Ala Ala Gly
 465 470 475 480
 Thr Ser Leu Glu Asp Ala Val Val His Gly Cys Leu Glu Leu Val Glu
 485 490 495
 Arg Asp Ala Ile Ala Leu Trp Trp Tyr Asn Arg Thr Arg Gln Pro Gly
 500 505 510
 Val Thr Leu Asp Ala Arg Asp Pro Trp Ile Thr Arg Leu Arg Ala Val
 515 520 525
 Leu Arg Asp Leu Gly Arg Thr Val Trp Ala Leu Asp Leu Thr Ser Asp
 530 535 540
 Leu Gly Ile Pro Val Val Ala Ala Val Ser Val Arg Thr Gly Gly Thr
 545 550 555 560
 Ala Glu Asp Ile Val Leu Gly Phe Gly Ala His Phe Asp Pro Arg Ile
 565 570 575
 Ala Leu Arg Arg Ala Leu Thr Glu Leu Ser Gln Met Leu Pro Pro Leu
 580 585 590

Arg Leu Gln Arg Leu Gln Gln Ala Val Leu Ser Ala Glu Pro Trp Leu
245 250 255

Asp Ala Pro Arg Tyr Gly Gly Asp Pro Val Phe Asp Arg Met Ile Ser
260 265 270

<210> 3

<211> 434

<212> PRT

<213> *Streptomyces galilaeus*

<400> 3

Met Thr Ser Asp Thr Lys Ala Leu Val Leu Glu Gln Val Arg Glu Tyr
1 5 10 15

His Arg Gln Gln Gln Pro Gly Asn Phe Gln Pro Gly Val Thr Pro Ile
20 25 30

Leu Ser Ser Gly Ala Val Leu Asp Glu Glu Asp Arg Val Ala Leu Val
35 40 45

Glu Ala Ala Leu Asp Leu Arg Ile Ala Ala Gly Ala His Ser Arg Arg
50 55 60

Phe Glu Ser Lys Phe Ala Arg His Ile Gly Val Arg Lys Ala His Leu
65 70 75 80

Val Asn Ser Gly Ser Ser Ala Asn Leu Leu Ala Leu Ser Ala Leu Thr
85 90 95

Ser Pro Arg Leu Gly Glu Gln Arg Leu Arg Pro Gly Asp Glu Val Ile
100 105 110

Thr Val Ala Gly Gly Phe Pro Thr Thr Val Asn Pro Ile Leu Gln Asn
115 120 125

Gly Leu Thr Pro Val Phe Val Asp Leu Glu Leu Gly Thr Tyr Asn Thr
130 135 140

Thr Val Glu His Val Arg Ala Ala Ile Ser Asp Arg Thr Arg Ala Ile
145 150 155 160

Met Ile Ala His Thr Leu Gly Asn Pro Tyr Gln Val Ala Glu Ile Gln
165 170 175

Gln Leu Ala Thr Glu His Glu Leu Phe Leu Ile Glu Asp Asn Cys Asp
180 185 190

Ala Val Gly Ser Thr Tyr Gln Gly Arg Met Thr Gly Thr Phe Gly Asp
195 200 205

Leu Ala Thr Val Ser Phe Tyr Pro Ala His His Ile Thr Thr Gly Glu
210 215 220

Gly Gly Cys Val Leu Thr Arg Asn Leu Glu Leu Ala Arg Ile Val Glu
225 230 235 240

Ser Phe Arg Asp Trp Gly Arg Asp Cys Trp Cys Glu Pro Gly Glu Asp
245 250 255

Asn Thr Cys Leu Lys Arg Phe Asp Tyr Gln Leu Gly Asn Leu Pro Lys
260 265 270

Gly Tyr Asp His Lys Tyr Ile Phe Ser His Ile Gly Tyr Asn Leu Lys
 275 280 285
 Ala Thr Asp Leu Gln Gly Ala Leu Ala Leu Ser Gln Leu Asn Lys Leu
 290 295 300
 Pro Glu Phe Gly Ala Ala Arg Arg Arg Asn Trp Gln Arg Leu Arg Asp
 305 310 315 320
 Gly Leu Ala Asp Val Pro Gly Leu Leu Leu Pro Val Ala Thr Pro Gly
 325 330 335
 Ser Asp Pro Ser Trp Phe Gly Phe Val Ile Thr Val Leu Pro Asp Ala
 340 345 350
 Thr Tyr Thr Arg Arg Asp Leu Val Ala Phe Leu Glu Glu Arg Arg Ile
 355 360 365
 Gly Thr Arg Arg Leu Phe Gly Gly Asn Leu Thr Arg His Pro Ala Tyr
 370 375 380
 Leu Gly Thr Pro His Arg Val Ala Gly Asp Leu Arg Asn Ser Asp Ile
 385 390 395 400
 Ile Thr Glu Gln Ser Phe Trp Ile Gly Val Tyr Pro Gly Ile Thr Glu
 405 410 415
 Glu Met Thr Asp Tyr Met Arg Glu Ser Ile Val Glu Phe Val Thr Lys
 420 425 430
 Asn Gly

<210> 4
 <211> 329
 <212> PRT
 <213> *Streptomyces galilaeus*

<400> 4
 Met Pro Lys Asp Thr Pro Arg Pro Val Leu Arg Ile Gly Val Leu Gly
 1 5 10 15
 Cys Ala Asp Ile Ala Val Arg Arg Ile Leu Pro Ala Ile Val Glu His
 20 25 30
 Pro Ser Val Arg Leu Val Ala Leu Ala Ser Arg Asp Gly Ala Arg Ala
 35 40 45
 Glu Arg Leu Ala Ala Arg Phe Gly Cys Ala Ala Val Thr Gly Tyr Lys
 50 55 60
 Ala Leu Leu Asp Arg Glu Asp Ile Asn Ala Val Tyr Val Pro Leu Pro
 65 70 75 80
 Pro Gly Met His His Glu Trp Val Thr Glu Ala Leu Thr Ala Gly Lys
 85 90 95
 His Val Leu Val Glu Lys Pro Leu Ser Thr Thr Tyr Ala Gln Ser Val
 100 105 110
 Asp Leu Val Ala Met Ala Gly Arg Leu Gly Leu Ala Leu Thr Glu Asn
 115 120 125
 Phe Met Phe Leu His His Ser Gln His Glu Ala Val Arg Ala Met Thr
 130 135 140

Gly Glu Ile Gly Glu Leu Arg Val Phe Thr Ser Ser Phe Gly Val Pro
 145 150 155 160
 Pro Pro His Pro Ser Phe Arg His Asp Ala Arg Leu Gly Gly Gly
 165 170 175
 Ala Leu Leu Asp Val Gly Val Tyr Pro Leu Arg Ala Ala Gln Leu His
 180 185 190
 Leu Ala Gly Glu Leu Asp Val Leu Gly Ala Cys Leu Arg Val Asp Glu
 195 200 205
 Ala Thr Gly Val Asp Val Ala Gly Ser Ala Leu Leu Ser Thr Ala Thr
 210 215 220
 Gly Val Thr Ala Gln Leu Asp Phe Gly Phe Gln His Ala Tyr Arg Ser
 225 230 235 240
 Val Tyr Ala Leu Trp Gly Ser Arg Gly Arg Leu Ser Val Pro Arg Ala
 245 250 255
 Phe Thr Pro Pro Arg Glu His Arg Pro Val Val Arg Ile Glu Gln Gln
 260 265 270
 Asp Arg Leu Thr Glu Val Thr Leu Pro Ala Asp His Gln Val Gly Asn
 275 280 285
 Ala Leu Asp Ala Phe Ala Ser Ala Val His Ser Glu Thr Val Arg Ala
 290 295 300
 Ser Leu Gly Glu Ala Leu Leu Arg Gln Ala Leu Leu Val Glu Gln Val
 305 310 315 320
 Arg Lys Ala Ala Arg Val Val Ser Gly
 325

<210> 5

<211> 323

<212> PRT

<213> *Streptomyces galilaeus*

<400> 5

Met Arg Val Leu Ile Thr Gly Gly Ala Gly Phe Ile Gly Ser His Tyr
 1 5 10 15
 Val Arg Ser Leu Leu Ala Gly Thr Leu Pro Gly Pro Arg Pro Ser Arg
 20 25 30
 Val Thr Val Val Asp Leu Leu Thr Tyr Ala Gly Asp Thr Gly Asn Leu
 35 40 45
 Pro Leu Ala Asp Pro Arg Leu Asp Phe Arg Arg Leu Asp Ile Arg Asp
 50 55 60
 Leu Asp Ala Leu Leu Thr Val Val Pro Gly His Asp Ala Val Val His
 65 70 75 80
 Phe Ala Ala Glu Thr His Val Asp Arg Ser Leu Ser Glu Pro Ala Glu
 85 90 95
 Phe Val Arg Thr Asn Val Leu Gly Thr Gln Ser Leu Leu Glu Ala Ser
 100 105 110
 Leu Arg Gly Gly Val Gly Thr Phe Val His Val Ser Thr Asp Glu Val
 115 120 125

Tyr Gly Ser Ile Ala Gln Gly Thr Trp Thr Glu Glu Ala Pro Leu Leu
 130 135 140
 Pro Asn Ser Pro Tyr Ala Ala Ser Lys Ala Gly Ser Asp Leu Val Ala
 145 150 155 160
 Arg Ser Tyr Trp Arg Thr His Gly Leu Asp Val Arg Thr Thr Arg Cys
 165 170 175
 Ala Asn Asn Tyr Gly Pro Arg Gln His Pro Glu Lys Leu Ile Pro Leu
 180 185 190
 Phe Val Thr Glu Leu Leu Ala Gly Arg Pro Val Pro Leu Tyr Gly Asp
 195 200 205
 Gly Gly Asn Val Arg Glu Trp Leu His Val Asp Asp His Cys Arg Ala
 210 215 220
 Val His Ala Val Leu Thr Gly Gly Arg Pro Gly Glu Ile Tyr Asn Ile
 225 230 235 240
 Gly Gly Gly Thr His Leu Thr Asn Arg Glu Met Thr Ala Lys Leu Leu
 245 250 255
 Ala Leu Cys Gly Thr Asp Trp Ser Arg Val Arg Gln Val Pro Asp Arg
 260 265 270
 Lys Gly His Asp Leu Arg Tyr Ala Val Asp Asp Thr Lys Ile Arg Glu
 275 280 285
 Glu Leu Gly Tyr Arg Pro Leu Arg Ser Leu Asp Asp Gly Leu Arg Glu
 290 295 300
 Val Val Asp Trp Tyr Arg Asp Arg Gln Thr His Arg Pro Glu Pro Ala
 305 310 315 320
 Glu Arg Val

<210> 6
 <211> 443
 <212> PRT
 <213> *Streptomyces galilaeus*

<400> 6
 Met Arg Val Leu Leu Thr Ser Phe Ala Leu Asp Ala His Phe Asn Gly
 1 5 10 15
 Ser Val Pro Leu Ala Trp Ala Leu Arg Ala Ala Gly His Glu Val Arg
 20 25 30
 Val Ala Ser Gln Pro Ala Leu Thr Ala Ser Ile Thr Ala Ala Gly Leu
 35 40 45
 Thr Ala Val Pro Val Gly Ala Asp Pro Arg Leu Asp Glu Met Val Lys
 50 55 60
 Gly Val Gly Asp Ala Val Leu Ser His His Ala Asp Gln Ser Leu Asp
 65 70 75 80
 Ala Asp Thr Pro Gly Gln Leu Thr Pro Ala Phe Leu Gln Gly Trp Asp
 85 90 95
 Thr Met Met Thr Ala Thr Phe Tyr Thr Leu Ile Asn Asp Asp Pro Met
 100 105 110

Val Asp Asp Leu Val Ala Phe Ala Arg Gly Trp Glu Pro Asp Leu Ile
 115 120 125
 Leu Trp Glu Pro Phe Thr Phe Ala Gly Ala Val Ala Ala Lys Val Thr
 130 135 140
 Gly Ala Ala His Ala Arg Leu Leu Ser Phe Pro Asp Leu Phe Met Ser
 145 150 155 160
 Met Arg Arg Ala Tyr Leu Ala Gln Leu Gly Ala Ala Pro Ala Gly Pro
 165 170 175
 Ala Gly Gly Asn Gly Thr Thr His Pro Asp Asp Ser Leu Gly Gln Trp
 180 185 190
 Leu Glu Trp Thr Leu Gly Arg Tyr Gly Val Pro Phe Asp Glu Glu Ala
 195 200 205
 Val Thr Gly Gln Trp Ser Val Asp Gln Val Pro Arg Ser Phe Arg Pro
 210 215 220
 Pro Ser Asp Arg Pro Val Val Gly Met Arg Tyr Val Pro Tyr Asn Gly
 225 230 235 240
 Pro Gly Pro Ala Val Val Pro Asp Trp Leu Arg Val Pro Pro Thr Arg
 245 250 255
 Pro Arg Val Cys Val Thr Leu Gly Met Thr Ala Arg Thr Ser Glu Phe
 260 265 270
 Pro Asn Ala Val Pro Val Asp Leu Val Leu Lys Ala Val Glu Gly Leu
 275 280 285
 Asp Ile Glu Val Val Ala Thr Leu Asp Ala Glu Glu Arg Ala Leu Leu
 290 295 300
 Thr His Val Pro Asp Asn Val Arg Leu Val Asp His Val Pro Leu His
 305 310 315 320
 Ala Leu Leu Pro Thr Cys Ala Ala Ile Val His His Gly Gly Ala Gly
 325 330 335
 Thr Trp Ser Thr Ala Leu Val Glu Gly Val Pro Gln Ile Ala Met Gly
 340 345 350
 Trp Ile Trp Asp Ala Ile Asp Arg Ala Gln Arg Gln Gln Ala Leu Gly
 355 360 365
 Ala Gly Leu His Leu Pro Ser His Glu Val Thr Val Glu Gly Leu Arg
 370 375 380
 Gly Arg Leu Val Arg Leu Leu Asp Glu Pro Ser Phe Thr Ala Ala Ala
 385 390 395 400
 Ala Arg Leu Arg Ala Glu Ala Glu Ser Glu Pro Thr Pro Ala Gln Val
 405 410 415
 Val Pro Val Leu Glu Arg Leu Thr Ala Gln His Arg Ala Arg Glu Pro
 420 425 430
 Arg Arg Pro Gly Gly Thr Ser Pro Cys Val Ser
 435 440

<210> 7
 <211> 443
 <212> PRT
 <213> *Streptomyces galilaeus*

<400> 7
 Val Gln Thr Gln Asn Ala Pro Glu Thr Ala Glu Asn Gln Gln Thr Asp
 1 5 10 15
 Ser Glu Leu Gly Arg His Leu Leu Thr Ala Arg Gly Phe His Trp Ile
 20 25 30
 Tyr Gly Thr Ser Gly Asp Pro Tyr Ala Leu Thr Leu Arg Ala Glu Ser
 35 40 45
 Asp Asp Pro Ala Leu Leu Thr Arg Arg Ile Arg Glu Ala Gly Thr Pro
 50 55 60
 Leu Trp Gln Ser Thr Thr Gly Ala Trp Val Thr Gly Arg His Gly Val
 65 70 75 80
 Ala Ala Glu Ala Leu Ala Asp Pro Arg Leu Ala Leu Arg His Ala Asp
 85 90 95
 Leu Pro Gly Pro Gln Arg His Val Phe Ser Asp Ala Trp Ser Asn Pro
 100 105 110
 Gln Leu Cys His Ile Ile Pro Leu Asp Arg Ala Phe Leu His Ala Ser
 115 120 125
 Asp Ala Asp His Thr Arg Trp Ala Arg Ser Ala Ser Ala Val Leu Gly
 130 135 140
 Ser Ala Gly Gly Ala Pro Ala Glu Gly Val Arg Glu His Ala Gly Arg
 145 150 155 160
 Val His Arg Glu Ala Ala Asp Arg Thr Gly Asp Ser Phe Asp Leu Met
 165 170 175
 Ala Asp Tyr Ser Arg Pro Val Ala Thr Glu Ala Ala Ala Glu Leu Leu
 180 185 190
 Gly Val Pro Ala Ala Gln Arg Glu Arg Phe Ala Ala Thr Cys Leu Ala
 195 200 205
 Leu Gly Val Ala Leu Asp Ala Ala Leu Cys Pro Gln Pro Leu Ala Val
 210 215 220
 Thr Arg Arg Leu Thr Glu Ala Val Glu Asp Val Arg Ala Leu Val Gly
 225 230 235 240
 Asp Leu Val Glu Ala Arg Arg Thr Gln Pro Gly Asp Asp Leu Leu Ser
 245 250 255
 Ala Val Leu His Ala Gly Ser Ser Ala Ala Ser Ala Gly Gln Asp Ala
 260 265 270
 Leu Ala Val Gly Val Leu Thr Ala Val Val Gly Val Glu Val Thr Ala
 275 280 285
 Gly Leu Ile Asn Asn Thr Leu Glu Ser Leu Leu Thr Arg Pro Val Gln
 290 295 300
 Trp Ala Arg Leu Gly Glu Asn Pro Glu Leu Ala Ala Gly Ala Val Glu
 305 310 315 320

Figure 1 shows a 5x5 grid of dots. A circle is drawn around the dot at row 2, column 1. The grid is labeled with '1' through '25' in a 5x5 arrangement.

<400>	8														
Val	Asn	Arg	Ala	Ala	Arg	Pro	Thr	Val	Arg	Gly	Met	Ser	Ala	Ile	Ala
1				5					10					15	
Glu	Pro	Thr	Ala	Pro	Arg	Gly	Val	Ile	Val	Thr	Gly	Gly	Gly	Thr	Gly
			20					25					30		
Ile	Gly	Arg	Ala	Thr	Ala	His	Ala	Phe	Ala	Asp	Arg	Gly	Asp	Arg	Val
		35				40						45			
Leu	Val	Val	Gly	Arg	Thr	Ala	Ala	Thr	Leu	Ala	Gly	Thr	Ala	Glu	Gly
	50					55					60				
His	Pro	Gly	Ile	Ser	Val	Leu	Thr	Ala	Asp	Leu	Thr	Asp	Pro	Asp	Gly
65					70					75					80
Pro	Arg	Ala	Ile	Thr	Asp	Ala	Ala	Leu	Asp	Ala	Leu	Gly	Arg	Ile	Asp
				85					90					95	
Val	Leu	Val	Asn	Asn	Ala	Ala	Thr	Gly	Gly	Phe	Ala	Gly	Leu	Ala	Glu
			100					105					110		
Thr	Glu	Pro	Glu	Ala	Ala	Arg	Glu	Gln	Phe	Asp	Ser	Asn	Leu	Leu	Ala
		115					120					125			
Pro	Leu	Leu	Leu	Thr	Arg	Gln	Thr	Leu	Asp	Ala	Leu	Ser	Ala	Asp	Gly
	130					135					140				
Gly	Gly	Thr	Val	Leu	Asn	Ile	Gly	Ser	Ala	Gly	Ala	Leu	Gly	Arg	Arg
145					150					155					160
Ala	Trp	Pro	Gln	Asn	Gly	Val	Tyr	Gly	Ala	Ala	Lys	Ala	Gly	Leu	Asp
				165					170					175	
Phe	Leu	Thr	Arg	Thr	Trp	Ala	Val	Glu	Leu	Ala	Pro	Arg	Gly	Ile	Arg
			180					185					190		

Val Leu Gly Leu Ala Pro Gly Val Ile Asp Thr Gly Ile Gly Glu Arg
 195 200 205
 Ser Gly Met Ser Arg Glu Ala Tyr Ala Gly Phe Leu Gly Gln Ile Ala
 210 215 220
 Ala Arg Val Pro Ala Gly Arg Val Gly Arg Pro Glu Asp Ile Ala Trp
 225 230 235 240
 Trp Ala Val Gln Leu Ala Asp Pro Arg Ala Ala Tyr Ala Thr Gly Ala
 245 250 255
 Val Leu Ala Val Asp Gly Gly Leu Ser Leu Thr
 260 265

<210> 9
 <211> 144
 <212> PRT
 <213> *Streptomyces galilaeus*

<400> 9
 Met Thr Ala Gln Ala Pro Thr Ala Pro Ala Asp Val Tyr Ala Glu Val
 1 5 10 15
 Gln His Phe Tyr Ala Arg Gln Met Arg Tyr Leu Asp Ser Gly Glu Ala
 20 25 30
 Glu Thr Trp Ala Gly Thr Phe Thr Glu Asp Gly Ser Phe Ala Pro Pro
 35 40 45
 Ser Leu Pro Glu Pro Val Arg Gly Arg Pro Leu Leu Ala Glu Gly Ala
 50 55 60
 Arg Asn Ala Ala Ala Gly Leu Ala Ala Ala Arg Glu Thr His Arg His
 65 70 75 80
 Trp Val Gly Met Leu Thr Val Thr Pro Ala Asp Asp Gly Ser Leu Thr
 85 90 95
 Ala Glu Ser Leu Val Ser Ile Val Ala Val Ala Gln Gly Gly Pro Ala
 100 105 110
 Arg Leu His Leu Val Cys Thr Cys Arg Asp Val Leu Val Arg Glu Gly
 115 120 125
 Gly Arg Leu Leu Val Arg Glu Arg Val Val Thr Arg Asp Asp Arg Pro
 130 135 140

<210> 10
 <211> 259
 <212> PRT
 <213> *Streptomyces galilaeus*

<400> 10
 Val Arg Ile Ile Asp Leu Ser Ser Pro Val Asp Ala Ala Gly Phe Glu
 1 5 10 15
 Pro Asp Pro Val Val His Asp Val Leu Gly Pro Lys Glu Ala Ala Thr
 20 25 30
 His Met Ser Glu Glu Met Arg Glu His Phe Gly Ile Asp Phe Asp Pro
 35 40 45

Ala Glu Leu Pro Glu Gly Glu Phe Leu Ser Leu Asp Arg Leu Gln Leu
50 55 60

Thr Thr His Thr Gly Thr His Val Asp Ala Pro Ser His Tyr Gly Thr
65 70 75 80

Arg Ala Ala Tyr Arg Asp Gly Pro Pro Arg His Ile Asp Glu Met Pro
85 90 95

Leu Asp Trp Phe Phe Arg Pro Ala Val Val Leu Asp Leu Ser Asp Gln
100 105 110

Gly Thr Gly Ala Val Gly Ala Asp Val Leu Arg Arg Glu Met Asp Arg
115 120 125

Ile Gly His Thr Pro Ser Pro Met Asp Ile Val Leu Leu Arg Thr Gly
130 135 140

Ala Asp Ala Trp Ala Gly Thr Pro Lys Tyr Phe Thr Asp Phe Thr Gly
145 150 155 160

Leu Asp Gly Ser Ala Val His Leu Leu Leu Asp Leu Gly Val Arg Val
165 170 175

Ile Gly Thr Asp Ala Phe Ser Leu Asp Ala Pro Phe Gly Asp Ile Ile
180 185 190

Thr Arg Tyr Arg Ala Thr Gly Asp Pro Ser Val Leu Trp Pro Ala His
195 200 205

Val Ile Gly Arg Asp Arg Glu Tyr Cys Gln Val Glu Arg Leu Ala Gly
210 215 220

Leu Asp Arg Leu Pro Ala Ala His Gly Phe Arg Val Ala Cys Phe Pro
225 230 235 240

Val Arg Ile Ala Gly Ala Gly Ala Gly Trp Thr Arg Ala Val Ala Leu
245 250 255

Val Asp Glu

<210> 11
<211> 238
<212> PRT
<213> *Streptomyces galilaeus*

<400> 11
Met Tyr Gly Arg Glu Leu Ala Asp Val Tyr Glu Ala Ile Tyr Arg Ser
1 5 10 15

Arg Gly Lys Asp Trp Gly Gln Glu Ala Ala Asp Val Ser Arg Ile Ile
20 25 30

Thr Glu Arg Arg Pro Gly Ala Gly Ser Leu Leu Asp Val Ala Cys Gly
35 40 45

Thr Gly Ala His Leu Ser Val Phe Ser Thr Leu Phe Glu Val Ala Glu
50 55 60

Gly Leu Glu Ile Ala Glu Pro Met Arg Arg Leu Ala Glu Gln Arg Leu
65 70 75 80

Pro Gly Thr Thr Val His Ala Gly Asp Met Arg Asp Phe Arg Leu Pro
85 90 95

Arg Thr Tyr Asp Ala Val Ser Cys Met Phe Cys Ala Ile Gly Tyr Leu
 100 105 110
 Glu Thr Leu Asp Asp Met Arg Ala Ala Val Arg Ser Met Ala Ala His
 115 120 125
 Leu Glu Pro Gly Gly Val Leu Val Val Glu Pro Trp Trp Phe Pro Glu
 130 135 140
 Asn Phe Ile Glu Gly Tyr Val Ala Gly Asp Leu Ala Arg Glu Glu His
 145 150 155 160
 Arg Thr Ile Ala Arg Ile Ser His Thr Thr Arg Lys Gly Arg Ala Thr
 165 170 175
 Arg Met Glu Val Arg Phe Thr Val Gly Asp Ala Ala Gly Ile Gln Gln
 180 185 190
 Phe Thr Glu Ile Asp Val Leu Thr Leu Phe Thr Arg Asp Glu Tyr Thr
 195 200 205
 Ala Ala Phe Thr Asp Ala Gly Cys Ser Val Glu Phe Leu Glu Asp Gly
 210 215 220
 Pro Thr Gly Arg Gly Leu Phe Val Gly Val Arg Glu Gln Arg
 225 230 235

<210> 12
 <211> 291
 <212> PRT
 <213> *Streptomyces galilaeus*

<400> 12
 Met Lys Gly Ile Ile Leu Ala Gly Gly Ser Gly Thr Arg Leu His Pro
 1 5 10 15
 Ile Thr Val Ser Val Ser Lys Gln Leu Leu Pro Val Gly Asp Lys Pro
 20 25 30
 Met Ile Tyr Tyr Pro Leu Ser Val Leu Met Leu Ala Asp Ile Arg Glu
 35 40 45
 Ile Leu Leu Ile Cys Thr Glu Arg Asp Leu Glu Gln Phe Arg Arg Leu
 50 55 60
 Leu Gly Asp Gly Ser Gln Leu Gly Leu Arg Ile Asp Tyr Ala Val Gln
 65 70 75 80
 Asn Arg Pro Ala Gly Leu Ala Asp Ala Phe Val Ile Gly Ala Asp His
 85 90 95
 Val Gly Asp Asp Asp Val Ala Leu Val Leu Gly Asp Asn Ile Phe His
 100 105 110
 Gly His His Phe Tyr Asp Leu Leu Gln Ser Asn Val His Asp Val Gln
 115 120 125
 Gly Cys Val Leu Phe Gly Tyr Pro Val Glu Asp Pro Glu Arg Tyr Gly
 130 135 140
 Val Gly Glu Thr Asp Ala Ser Gly Gln Leu Val Ser Leu Glu Glu Lys
 145 150 155 160
 Pro Leu Arg Pro Arg Ser Asp Leu Ala Ile Thr Gly Leu Tyr Leu Tyr
 165 170 175

Asp Asn Glu Val Val Asp Ile Ala Lys Asn Leu Arg Pro Ser Pro Arg
 180 185 190
 Gly Glu Leu Glu Ile Thr Asp Val Asn Arg Asn Tyr Leu Ala Arg Gly
 195 200 205
 Arg Ala Arg Leu Val Asp Leu Gly Arg Gly Phe Ala Trp Leu Asp Ala
 210 215 220
 Gly Thr Pro Glu Ser Leu Leu Gln Ala Thr Gln Tyr Val Arg Thr Leu
 225 230 235 240
 Glu Glu Arg Gln Gly Val Arg Ile Ala Cys Val Glu Glu Val Ala Leu
 245 250 255
 Arg Met Gly Phe Ile Asp Ala Asp Met Cys His Arg Leu Gly Glu Gln
 260 265 270
 Met Ser Gln Ser Gly Tyr Gly Arg Tyr Val Met Ala Val Ala Arg Glu
 275 280 285
 Phe Ser Gly
 290

<210> 13
 <211> 341
 <212> PRT
 <213> *Streptomyces galilaeus*

<400> 13
 Met Thr Thr Leu Val Trp Asp Tyr Leu Gln Glu Tyr Glu Asn Glu Arg
 1 5 10 15
 Ala Asp Ile Leu Asp Ala Val Glu Thr Val Phe Ser Ser Gly Arg Leu
 20 25 30
 Val Leu Gly Asp Ser Val Arg Gly Phe Glu Glu Glu Phe Ala Ala Tyr
 35 40 45
 His Gly Ala Ala His Cys Val Gly Val Asp Asn Gly Thr Asn Ala Ile
 50 55 60
 Lys Leu Ala Leu Gln Ala Leu Gly Val Gly Pro Gly Asp Glu Val Val
 65 70 75 80
 Thr Val Ser Asn Thr Ala Ala Pro Thr Val Val Ala Ile Asp Ser Val
 85 90 95
 Gly Ala Thr Pro Val Phe Val Asp Val His Pro Asp Ser Tyr Leu Met
 100 105 110
 Asp Thr Glu Gln Val Glu Ala Ala Leu Thr Pro Arg Thr Arg Cys Leu
 115 120 125
 Leu Pro Val His Leu Tyr Gly Gln Cys Val Asp Leu Ala Pro Leu Glu
 130 135 140
 Arg Leu Ala Ala Glu His Asp Leu Phe Leu Val Glu Asp Cys Ala Gln
 145 150 155 160
 Ala His Gly Ala Arg Arg Ala Gly Arg Leu Ala Gly Thr Thr Gly Asp
 165 170 175
 Ala Ala Ala Phe Ser Phe Tyr Pro Thr Lys Val Leu Gly Ala Tyr Gly
 180 185 190

ggcggaccgc	gcctgaagac	cggtgagggg	ccggtaggcc	cggtcggggc	ggtcggcccc	1800
gtcctgggga	taggcgcaca	gcagtcgccg	gtccagcagc	cggttcacga	gcccgtcggc	1860
gagtcgggcc	ggcagccggg	gtgccgcgtc	ggcgacgatg	cccggcagat	cgcggtcgcc	1920
gtcagagcagc	ggggccagca	gggcgatctg	ctccccgccc	agcgtggatc	cccggctcctc	1980
ggtcatcagg	tagacgggct	ctccccggccg	cgactcgacc	cgagatgcg	gtgcgaaccc	2040
cagccggggg	agcccgttgc	cagggggccgt	acggctcatc	gagacgcagg	gcccgcgacc	2100
gtggccgacg	gggtgctgga	aaggggagcc	cagcagatac	agatcgcgct	gtccgcgtgc	2160
tccccgggac	cgttgccgaa	ctccgtgatg	acgagatcgt	cggcgaactc	ggcggtcgcc	2220
gcgtcacctt	ccaggagggg	cgtgatccgt	gacatgtgtg	ctccttgctg	ctgtcgggccg	2280
gctgctgtga	gtagtgtctc	ggccctgggt	cgagctgtgc	actgccgtca	tccttacggc	2340
ccgtcagggc	ggctgccagt	gcgtctggca	taccgtgcct	atgaggttta	cacatcttgc	2400
acatacgttc	ctcatgtgcc	tggtcggggt	cagggcactg	gttgattgcc	gaagtggcca	2460
gcaagactcc	ctgagcatgg	agctcttcgc	ggtgctccgt	cgaccagatg	ggggagaaga	2520
acgtggacat	atggttgcgt	ggaccgctga	cgcccgagg	gcggggcagg	tcgatcgtgc	2580
ccaccgcggc	gaaaccccga	cagatccctg	ccctgctcgc	catccacgcc	aatcgcgctc	2640
tgcccgctcg	gaccctgatg	gaggagatct	ggggcaccga	gccgccccag	agcgccctcg	2700
ccaccctgca	cacgtacatc	ctccagctgc	gccgcgggct	gaccgctgcc	tacggtgacg	2760
agggggggcgt	gtccgccaag	gacgtcctcg	tcacccagta	cggcggctac	tgctggcagg	2820
cgcccacgga	ctccgtggac	gtaccgcgct	acgaacggct	cgtcaccgcc	ggacgggatcg	2880
ccaccgcgga	ggaccggcag	gaggaggcgt	cgcccactt	ccgtgaggca	ctcgcgctct	2940
ggcggggggtc	cgcgctgggtg	gacgtgcgga	tcggaccggg	cctgagcatc	gaggtggcgc	3000
ggctggagga	gagcaggctc	ggcgtgctgg	agcgtgcct	ggaggcggac	ctgaggctgg	3060
gacgccacgc	ggagctgctg	gccgaactca	cgaactcac	cgggcgccat	ccgctgcacg	3120
agggcctgca	cgcccagtg	atgacggcgc	tgtaaccggg	gggcgctcc	ggcgaggcgc	3180
tggacgtcta	ccagaggctg	cgccgcgggc	tgggcgagga	actcggaactc	tccccgtcgc	3240
cgcgcctgca	gcgtctgcag	caggcggtgc	tctcgcgga	gccctggctg	gacgcgcccc	3300
ggtacggagg	ggaccgggtg	ttcgaccgga	tgatcagctg	accgtcccgg	cggtcagcc	3360
gttcttggtg	acgaactcga	cgatggactc	ccgcagttag	tcggtcatct	ctccgtgat	3420
gcccggatac	accccgatcc	agaagctctg	ctcggtgatg	atgtcgaggt	tgccgcgatc	3480
gcccggccacc	cggtgcggcg	tgccgaggtg	cgccggatgg	cggtgagggt	tgccgcgga	3540
cagccgcctg	gtgccgatcc	gccgttcctc	caggaaggcg	accaggtcac	ggcggtgta	3600
ggtggcgctg	ggcaggaccg	tgatcacgaa	cccgaaccag	ctgggatcgc	tgcccgggtg	3660
cgcgaccggc	agcagcagac	cggggacgct	ggcgagcccg	tcccgcagcc	gctgccagtt	3720
gcgcgcggcg	gccgcgccga	actccggcag	cttggtcaac	tggtgagtg	ccagcgcccc	3780
ttgcagatcg	gtcgccctca	ggttgtaacc	gatgtgggag	aagatgtact	tggtgtcgta	3840
gcccctgggg	agattaccca	gctggtagtc	gaaccgcttg	aggcagggtg	tgctctcgcc	3900
cggttcgcac	cagcagtcctc	ggccccagtc	gcggaacgac	tcgacgatgc	gggccaagt	3960
gaggttgccg	gtcagtacgc	agccccctc	gcccgtggg	atgtggtggg	caggatagaa	4020
actgacggtt	gccaggctccc	cgaaggctccc	gctcatacgt	ccctggtagg	tcgagccac	4080
cgcgtcgcag	ttgtcctcga	tcaggaacag	ctcgtgctcg	gtggccagtt	gctggatctc	4140
cgccacctgg	taggggttgc	cgagggtgtg	cgcgatcatg	atggcccggg	tccggtccga	4200
gatcgccggc	cgcacgtgct	ccaccgttgt	gttgtaacga	ccgagttcca	ggtccacgaa	4260
cacgggctgc	agcccgttct	ggaggatccg	gttcaccgtg	gtgggggaatc	cgccggccac	4320
cgtgacaccc	tcgtcacccg	gcgcagccg	ctgctcaccc	agccggggag	aggtcagcgc	4380
agagagcgcc	agcagggttcg	ccgaggaccc	cgagttcacc	aggtgcgcct	tgctacgccc	4440
gatgtggcgg	gcgaatttgc	tctcgaagcg	ccgggagtg	gctccggccg	cgatccgcag	4500
atccaggggc	gcctccacca	gggcgacccg	gtcctcctcg	tcaggagcgg	cgcccgagga	4560
gaggatgggc	gtcaactccg	gctggaaatt	ccctggctgc	tgctgcgggt	gatactcgcg	4620
aacctgctcc	aggaccagag	ccttggtgtc	cgacgtcata	gccgtccctc	cgtaaggatt	4680
gcctcgccga	ccatgctggc	ccggatccgt	cgaggagccg	tggaagtccc	gccgaaggcc	4740
ctgctccagt	gggcttcaag	gggccttcga	cctgccgtgg	ctagcgtgtc	cggcgacgca	4800
tcgaactggt	gaggtggcag	atgccgaagg	acactccacg	gcccgtactc	cgcacggggg	4860
ttctgggctg	tgccgatata	gcgggtgcgc	ggatccctgc	cgcgatcgtg	gagcatccgt	4920
cggtccggct	ggctcgtctg	gcgagccggg	acggggcgcg	cgccgaacgg	ctcgcgggcc	4980
gtttcggatg	cgcggcggtg	accggctaca	aggcgctgct	ggaccgtgag	gacatcaacg	5040
ccgtctacgt	tccccctgcg	cccggcatgc	accacgaatg	ggtcaccgaa	gcgctgacgg	5100
cgggcaagca	cgtgctgggt	gagaagccgc	tcagcacgac	gtacgcgcag	agcgtcgacc	5160
tggtggcgat	ggccggccgg	ctcgccctcg	cgctcaccca	gaacttcatg	ttcctgcacc	5220
actcgcagca	cgaggcggtc	cgggccatga	ccggcgagat	cggggaactg	cggtcttcca	5280
ccagttcctt	cggcgtgcgg	ccgccccacc	cctcgtcctt	ccggcacgac	gcgcggctcg	5340
gcggcgggcg	cctgctggac	gtcggtgtct	atccgctgcg	cgcgggccag	ctccacctcg	5400
ccgggggaact	cgacgtgctg	ggcgccctgc	tgccgctgga	cgaggcgacc	ggcgtcgacg	5460
tcgcgggaag	cgcgctgtcg	tcacagcgga	cggtgtgtac	cgcgcagctc	gacttcgggt	5520
tcagcacgcg	gtaccgggtc	gtgtacgcgc	tgtggggcag	ccgcggcagg	ctgagcgtgc	5580
cgcgggcctt	caccccgccc	cgtgagcacc	gcccgggtgt	ccgtatcgaa	cagcaggacc	5640
gtctcaccga	agtgaacgtg	cccgcggatc	accaggtggg	caacgcgctc	gacgcgttcg	5700
cctcggcggt	gcactcggag	accgtccgtg	cctccctggg	ggaggcgctg	ctgcgtcagg	5760

cgctcctggt	cgagcaggta	cgcaaagccg	cgcggttcgt	cagcggtga	gcccccgga	5820
cgctttgogg	gcgcctgacg	cccgcacgac	gagagnnnnn	nnnnnnnnnn	nnnnngggt	5880
ctcctcacac	tectcgcggt	cgcgccccgc	cggggcggt	cagaccgct	cggccggttc	5940
cgcccggtgg	gtctgcgggt	cgcggtacca	gtcgcagacc	tcgcgcagac	cgctcgccag	6000
ggaccgcagc	ggccggtagc	cgagttcttc	gcggatcttc	gtgtcgtcca	ccgcgtaccg	6060
caggtcgtgg	cccttgcggt	cgggcacctg	gcggaccctg	gaccagtcgg	tgccgcacag	6120
cgcgagcagc	ttggccgtca	tctcacggtt	cgtcagatgg	gtaccgcgcg	cgatgttgta	6180
gatctcgccg	ggccggccac	cggtcagcac	cgcgtggacg	gcccggcagt	ggtcgtccac	6240
gtgcagccat	tccttgacgt	tgctccgctc	gccgtacagc	ggcaccggcc	ggccggccag	6300
cagttcggtg	acgaacagcg	ggatgagctt	ctccgggtgc	tgacgggggc	cgtagttgtt	6360
ggcgcagcgg	gtcgtgcgca	catcgaggcc	gtgggtgcgc	cagtaggacc	gtgcgaccag	6420
gtcgcttccc	gccttcgagg	ccgcgtaggg	ggagtggggg	agcagcggcg	cctcctccgt	6480
ccaggtgccc	tgccgcgatcg	atccgtagag	ctcgctccgtg	gagacgtgca	cgaacgtgac	6540
gaccccgcgg	cgcaggctcg	cctccagcag	cgactgggtg	cccagtagct	tggtgcggac	6600
gaactccgcg	ggctcgctca	gcgaacggtc	gacatgggtc	tcggcccgca	agtgtacgac	6660
cgcgtcgtgg	ccggggacca	ccgtcagcag	cgcgtccagg	tcgcggatgt	cgagccggcg	6720
gaagtccagc	cggggatcgg	ccaggggcag	attgccgggtg	tctcccgcgt	acgtgagcag	6780
gtcgacgacg	gtgacccggc	tcggggcggg	accgggcagg	gtccccgcca	gcagggaacc	6840
gacgtagtgg	gacccgatga	aaccggcgcc	gccggtgac	aggacacgca	tgccgacgta	6900
cctccggggg	gtcgggggtc	acgggcgcgg	tgctgggcgg	tcagccgttc	cagtacgggg	6960
acgacctgcg	ccggggtcgg	ttcggactcg	gcctcgcccg	gcaggcgggc	ggccgcgcgg	7020
gtgaacgagg	gtcgtcgag	gagccggacg	agcctgccgc	gcagtccttc	caccgtcacc	7080
tcgtgcgagg	ggagatggag	gcccgcgcgg	agtgcctgct	gacgctgcgc	gcggtcgatc	7140
gcgtcccgag	tcagcccat	ggcgatctgc	ggcacacct	cgaccagcgc	cgctgaccag	7200
gtgcccggcg	cgcctgggtg	gacgatggcc	gcgcaggtcg	gcagcagcgc	gtgcagcggc	7260
acatggtcca	ccagacgcac	attgtcgggg	acatgggtca	gcagtgcgcg	ttcctcggcg	7320
tcgagggtgg	cgaccacctc	gatgtccagc	ccctcgaccg	ccttgaggac	gaggtcgacc	7380
gggacggcgt	tggggaactc	cgaggtccgg	gccgtcatgc	ccagggtgac	ccagacgcgg	7440
gggcgggtcg	gcgggacgcg	cagccagtgc	ggtacgacgg	caggccccgg	cccggtgtag	7500
gggacgtagc	gcatgcccac	gaccgggcgg	tcgcagggcg	ggcggaagct	gcgcggcacc	7560
tggtccaccg	accactgtcc	cgtcaccggc	tcctcgtcga	aggggacgcc	gtagcggccg	7620
agcgtccaat	ccagccactg	gccgagttag	tcgtcggggg	gcgtcgtccc	gttccccccc	7680
gcccggcccg	ccggggcggc	gccgagctgg	gcgaggtagg	cccgcgcgat	ggacatgaag	7740
aggtcccgga	aggacagcag	ccgggcgtgg	gccgcgcggg	tcaccttcgc	ggccaccgcg	7800
ccggcgaaag	tgaacggctc	ccacaggatc	aggtccgggt	cccagccgcg	ggcgaaacgc	7860
acgaggtcgt	cgaccatcgg	atcgtcgttg	atcagggtgt	agaagggtgg	ggtcatcatc	7920
gtgtcccgag	cctggagaaa	ggccgggggtg	agctgtccgg	gggtgtcggc	gtcagagcgc	7980
tggtcggcgt	ggtgggacag	cacagcgtcg	cccacgccct	tgaccatctc	gtccagccgg	8040
gggtccgcgc	ccaccggcac	ggcggtcagc	ccggccgcgc	tgatgctcgc	cgtcagcgcg	8100
ggctggctcg	ccaccgcac	ctcgtgcccg	gcggcccgca	acgcccaggc	cagcggcacc	8160
gacccggttg	agtgagcgtc	cagcgcgaag	gatgtcagga	gaaccgcgat	ggtcggctct	8220
ttctctgcgg	ctcggctttc	ggcggctcgc	aactcggggc	gcggcacgcc	gggccccggc	8280
gtgcccgtac	gcggaggtgg	tcagggggaa	gcgcagcacc	gcgcccagca	cgggggaaac	8340
catccgcgcg	aggaccgcgc	cggccggcgc	gagcacgggc	cggcgtctcc	gcagcgtcgc	8400
gaccgcggtc	tcgcctgga	gccgggcgaa	cgccccgaag	agcgcgggtg	gcgggcccga	8460
gagcgacaac	tgccccctgc	cggcgggacg	gtcgaggtcg	aagtggctcg	gggcccaggaa	8520
cgctctgggg	tcccgggttc	ccgcaccgac	atggacagcg	acctgggcgc	cggccgggag	8580
gtcctggccg	ccagggtgga	ggtcctcgcc	ggcgatacgg	ctctccagcc	gcaccggcgg	8640
cgcgaagcgc	agtgcctcct	ccacggcgcc	ggccgcgagt	tcagggttct	cgccgagccg	8700
cgcccaactg	acgggacggg	tgagcagcga	ctccagggtg	ttgttgatga	gccccggcgt	8760
gacctcgacg	ccgaccacgg	cggtcagcac	acccacggcg	agcgcgtcct	gccccggcga	8820
ggcggcgagg	gagccggcgt	gcagcaccgc	gctgagcagg	tcgtcaccgc	gctgcgtccg	8880
ccgcgctcgc	acgaggtcgc	gcagcagggc	ccgtacgtcc	tcgacggcct	cggtgagccg	8940
gcgggtcacg	gcgagcggct	gggggcagag	cgcggcgtcg	agggcgacac	cgagggcgag	9000
gcacgtcgcc	gcgaagcggt	cccgtcgggc	ggcggggaca	ccgagcagct	ccgcggcggc	9060
ctcgtggccc	accggggcgg	agtagtcggc	catgaggtcg	aagctgtccc	cggtagcgtc	9120
ggcggctccc	cggtgacgcg	gcccggcgtg	ctcgcggaca	ccctccgcgc	gggcgcgcgc	9180
cgcactgccc	aggacggcgg	aggcggaccg	cgcccagcgc	gtgtgggtcg	cgtccgacgc	9240
gtggagggaag	gcccgggtcca	gcgggatgat	gtggcacagc	tgccgattgc	tccaggcgtc	9300
ggagaagacg	tgccgctcgc	ggcccggcag	gtcggcgtgg	cgcagggcga	gcccgggatc	9360
ggccaggggc	tcggcgggcga	cgcctgtccc	gccggtgacc	caggcgccgg	tggtgctctg	9420
ccacagcgcc	gtcccggctt	cccgtatccg	gcgggtcagc	agcgcggggg	cgtcgtctct	9480
ggcgcgcagg	gtcaggcggt	acgggtcgcc	gctgggtgccc	tagatccagt	ggaagccgcg	9540
ggcggtcagg	agatgacggc	ccagttcgct	gtcggctctgc	tggttctccg	ccgtctcccg	9600
cgcgttctgt	gtctgcacgg	cagttctcct	cgggacgtgg	ttcagggtgag	ggacagaccg	9660
ccgtcgaccg	cgagcaccgc	tccggtcgcg	taagcggcgc	gcgggtcggc	cagctggacg	9720
gcccaccagg	cgatgtcctc	gggcccggcg	acccggccgc	ccgggacgcg	ggcggcgatc	9780

tgcccagagga	agcccgcgta	ggcctcccgt	gacatgcccg	agcgttcacc	gatgccgggtg	9840
tcgatcacgc	cgggcgccag	gccgaggaca	cggatgccgc	ggggtgccag	ttcgacggcc	9900
cagggtccggg	tgaggaagtc	gagcccggcc	ttggcgggcg	cgtagacacc	gttctgcggc	9960
caggccccggc	ggcccagagc	tccggccgag	ccgatgttca	gcacggttcc	cccgcgctcg	10020
gccgacaggg	cgtccagggc	ctgccgggtg	agcagcagcg	gggccaggag	gttgctgtcg	10080
aactgctcgc	gggcggcctc	cggtctgggtc	tccgccaggc	cggcgaaccc	accgggtggcc	10140
gcgttggttca	cgaggacgtc	gatacggccc	aacgcgtcca	gcgcgcgctc	ggtgatggcg	10200
cgcggaaccgt	ccggatcggt	gagatcgggc	gtcaggacac	tgatgccggg	gtggccctcg	10260
gcgggtcccgg	ccagggtcgc	ggcggtgcgg	cctacgacga	gtaccgggtc	gccgcggtcg	10320
gcgaaggcgt	gggcccgtggc	ccgcccgatc	ccggtcccgc	cgccggtgac	gatcacgccc	10380
cgcggcgctg	tcggttctgc	tatggcgctc	atgccccgga	ccgtaggccg	ggccgctcga	10440
ttcacggctcg	actcccgcctc	ggccgcggcc	tcaggggccg	tcgtcacggg	tcaccacgcg	10500
ttcccggacc	aggagccggc	cgccctcccg	gaccaggacg	tcccggcagg	tgcagaccag	10560
gtgcagccgg	gcggggccgc	cctgcgcgac	ggcgacgatc	gagaccaggc	tctcggcggt	10620
cagcgagccg	tcgtcccgcg	gggtgacggc	gagcatgccc	acccagtggc	ggtgcgtctc	10680
gcggggcgcg	gccagacccg	ccgcggcggt	gcgggcaccc	tcggcgagca	gcggggcgctc	10740
gcgtaccggc	tccgggagcg	agggcggtgc	gaaggagccg	tcctcggtga	aggtgccggc	10800
ccagggtctcg	gcctcgcccg	agtcacaggta	ccgcactctgc	cgtgcgtaga	aatgctgtac	10860
ctcggcgtag	acgtcccgccg	gggcccgtcgg	tgctgtgtgt	gtcatgcccgt	gtcacctttc	10920
gccgttcccg	cgtccgggac	gggtgcgtgc	ccgggtcccc	ggtgagtgtc	acgacggctcg	10980
cagcgcgact	ccaggatcgg	tcgagcgggg	ggcgggcgga	tgcgctggcg	gctgttcagt	11040
cagcctccaa	cgcttctcaa	gccgcgctgg	tgagcatggg	ctggctcgca	ggaacccatc	11100
gccgggaggg	gcgtgtgcgc	atcatcgacc	tgtcctcacc	cgtggacgcg	gcgggttttg	11160
aacctgatcc	cgtcgtgcac	gacgttctctg	gtccgaagga	ggccgccacg	cacatgagcg	11220
aggatagcgc	tgagcacttc	ggcatcgactc	tcgatccggc	ggaactgccg	gagggcgaaat	11280
tcctctcgct	cgaccgtctc	cagctgacca	cccacaccgg	aacccatgtc	gacgcgccct	11340
cgcactacgg	cacgcgcgcc	gcgtaccggg	acggtccgcc	gcggcacatc	gacgagatgc	11400
cgctcgactg	gttcttcccg	cccgcgcgtc	tcctcgacct	cagcgaccag	ggcacggggc	11460
cggtcgggcg	cgacgtgctg	cggcgggaga	tgacccggat	cgccacacat	ccctcgccca	11520
tggaacatcgt	cctgctcagg	accggtgcgc	acgcgtgggc	gggaaccccc	aaagtacttca	11580
cggacttcac	cgggctggac	ggttcggccg	tgacactgct	gctggacctg	ggggtgcggg	11640
tgatcggcac	ggacgcggtt	agcctggacg	cgccgttcgg	cgacatcatc	acccgctacc	11700
gggccacggg	cgacccgctc	gtcctgtggc	ccgcccatgt	catcggggcg	gaccgggagt	11760
actgcaggt	cgagcggctc	gccgggctcg	accggctgcc	cgccgcgcac	gggttccggg	11820
tcgcgtgctt	cccggtgccg	atcgccggag	cgggcgccgg	ctggacgagg	gcgggtggcc	11880
tggtcgacga	gtgaggagcg	cacggcgggc	cgagcggacg	acgcgccccac	cggggcgcgc	11940
acggagggaa	cagacatgta	cggcgcggaa	ctcgcgagac	tgtacgaggc	catctaccgc	12000
agcccgggca	aggactgggg	acaggaggcg	gcggacgtct	cgcgacatct	caccgaacgg	12060
cgtccgggag	ccggctcgct	gctcgacgtc	gcctgtggca	cgggcgccca	tctgagcgtg	12120
ttcagcacgc	tgttcgaggt	cgccgagggc	ctggagatcg	cggagccgat	gcggcggtct	12180
gccgagcagc	ggctgcccgg	caccaccgtg	cacgcgcggc	acatgcgcga	cttccggctc	12240
ccgcgcacct	acgacgcggg	gagctgcatg	ttctgcgcca	tcggctatct	ggagacgctg	12300
gacgacatgc	gggcccgcgt	ccggtcgatg	gcgctcatc	tggaagcccg	ggcggtgctg	12360
gtcgtcgaac	cctggtgggt	ccccgagaac	ttcatcgagg	gctatgtcgc	gggtgacctg	12420
ggccgcgagg	agcaccggac	catcgcccgg	atctcgcaca	ccaccgggaa	gggcccggcc	12480
acccgcgatg	aggttcgctt	caccgtgggg	gacgcgcgcg	gcacccagca	gttcacggag	12540
atcgacgtgc	tgaccctggt	caccagggac	gaatacaccc	ccgcggttcc	cgacgcgcgc	12600
tggttcggtg	aattcctgga	ggacggaccc	acccggccgc	gtcttttcgt	cgggtgttcg	12660
gaacagcgct	gagccggagg	aaggtcagcc	cgagaattct	cgggcgaccg	ccatcacata	12720
gcgaccgtaa	ccggactgcg	acatctgctc	accgagtcgg	tggcacatgt	ccgcgtcgat	12780
gaatcccatg	cgcagcgcga	cttcttcgac	gcaggcgatg	cgcacgcctt	gccgttcttc	12840
gagcgtgcgc	acgtactggg	tgccctgaag	cagcgattcc	ggggttccgg	gctcgagcca	12900
ggcgaacccg	cgcccgagat	cgaccagacg	cgctcgcccg	cgggccaggc	aattccgggt	12960
cacatcggtg	atctccagtt	cgccgcgcgg	cgagggccgg	aggttcttcg	cgatgtccac	13020
cacttcggtg	tcgtacagat	agagcccggc	gatggcgagg	tcggaacgcg	gccggagcgg	13080
cttctcctcc	agggagacga	gttgccccga	cgctcggttc	tcgcccacgc	cgtagcgtct	13140
cgggtccctcc	acggggtagc	cgaacagcac	gcagccctgg	acgtcgtgga	cggtgctctg	13200
gagcagctcg	tagaagtggc	gtccgtggaa	gatgttgtcc	ccgaggacca	gtgccacgtc	13260
gtcgtacccc	acgtggtcgg	cgccgatgac	gaaggcgtcg	gccagtccgg	ccggccgggt	13320
ctgcaccgcg	tagtcgatgc	gcaggccgag	ctgggagccg	tcgcccagga	gccggcgga	13380
ctgttccaga	tcgcgctcgg	tcagatgag	caggatctcc	ctgatgtccg	ccagcatcag	13440
caccgagagc	ggatagtaga	tcacgcgctt	gtgcgcgacc	ggaagaagct	gttttgatac	13500
ggagacgggt	atcggtgga	gccgtgttcc	cgaaccgcgc	gcgagaataa	ttcccttcat	13560
gggtatgccc	ctgtcctcga	tttcttctca	tgctaaccgac	cggattcgct	cggcagcaag	13620
ccggaaaatt	tctgggtccag	ggaaaatcga	gcggtaatag	agggaaattc	ggggttgtgg	13680
accggagcga	gaatgtgatg	tgctgcgagg	ggatggtgac	gccctgtggc	acggcatcgg	13740
cgtggcatcg	gcaaggcatc	ggcaagggga	ggaaaagaat	taatgacgac	tctcgtctgg	13800

gactacctac	aggaatacga	gaacgaacgc	gccgacattc	tggacgccgt	ggagacggtc	13860
ttcagctcgg	gtcggctcgt	cctcggtgac	agcgttcgcg	gattcgagga	ggagttcgcc	13920
gcgtaccacg	gcgcggcgca	ctgcgtcggg	gtcgacaacg	gcaccaacgc	gatcaagctg	13980
gccccccagg	cgctcggcgt	cggccccggg	gacgaggtcg	tcacgggtgc	caacaccgcg	14040
gccccccagg	tcgtggccat	cgattcgggtg	ggcgccaccc	cggtgttcgt	cgacgtccac	14100
ccggacagct	acctcatgga	caccgagcag	gtggaggccg	cactcacgcc	ccggaccgga	14160
tgcctgctgc	cggtccatct	ctacgggcag	tgcgtcgacc	tggctccgct	ggagcggctc	14220
gccgcggagc	acgacctgtt	cctcgtcag	gactgcgcac	aggcccacgg	tgcccgcgc	14280
gccggccggc	tcgccggcac	caccggcgac	gccgccgctt	tctccttcta	ccccacgaag	14340
gtgctcggcg	cctacggcga	cggaggcgcc	gtggtgacct	cccgggacga	caccaccgca	14400
gcgctgcgcc	gactgcgcta	ctacggcatg	gaggagcggt	actacgtcgt	cggcaccccg	14460
ggtcacaacg	cccggctcga	cgaggtccag	gccgagatcc	tgcggcgcaa	gctgcgccgg	14520
ctcgacacct	acatcgaggg	gcggcgggcc	gtcgcccggc	gctacgagga	cgggctcggc	14580
gacaccggcc	tggtgctccc	gcacaccgtc	cccggcaacg	agcacgtgta	ctacgtctac	14640
acgggtgcgc	acccgcggcg	cgacgacatc	atcaaggccc	tcaaggcgta	cgacatcgag	14700
ctgaacatca	gctatccctg	gcccgtgcac	accatgtccg	ggttcgccca	cctcggctac	14760
ggcaagggct	cgctgcccgt	caccgaggac	ctggccggcc	agatct		14806

<210> 15

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: degenerated
oligonucleotide primer

<400> 15

csggsgssgc sggsttcats gg

22

<210> 16

<211> 24

<212> DNA

<213> Artificial Sequence

<220>


<223> Description of Artificial Sequence: degenerated
oligonucleotide primer

<400> 16


gggwrctggy rsggscgta gttg

24

Figure 4



1, L-rhamnosyl-ε-rhodomyacinone



2, L-daunosaminy-ε-rhodomyacinone

THIS PAGE BLANK (USPTO)